Therapeutics Pipeline Program

Therapeutics Pipeline Program is sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF). The Michael J.

Fox Foundation funds research projects that aim to accelerate a cure for Parkinson's disease and improved therapies. This program supports the preclinical development of novel treatments targeting neurodegeneration in Parkinson's disease.

Parkinson's Disease Therapeutics Pipeline Program | Parkinson's Disease August is Make-a-Will Month. Plan for your future and help advance Parkinson's research. Learn how.

Search for topics, articles, videos, research, etc... Hit enter to search or ESC to close Parkinson's Disease Therapeutics Pipeline Program Parkinson's Disease Therapeutics Pipeline Program Our flagship funding initiative accelerates Parkinson’s disease therapy development by prioritizing opportunities where our funding supports generation of meaningful evidence informing critical development milestones.

Funding to accelerate pre-clinical and clinical development of disease-modifying or symptomatic interventions for Parkinson’s disease Program additionally supports integration and analysis of decision-informing biomarker tools Funding ranges of $1M-$5M for 2-3 years contingent on program scope and development stage Open to industry and academic + industry partnerships to foster clearer paths to commercialization; eligibility exemptions for academic-led projects in certain cases (access Overview document in sidebar for details) Pre-proposals accepted on a rolling basis for rapid initial exchange with MJFF on proposed therapeutic ideas Multiple annual review cycles for applicants invited to submit a full proposal Office hours are available to address questions and partnerships after invite to the full proposal round As the primary focus of TPP is to advance new therapeutic interventions, MJFF will NOT consider proposal submissions to this program that focus on the following areas: Early-stage target discovery (e.g., genomic/transcriptomic analyses) Validation studies using tool compounds or manipulation methods that lack a clear and viable path to therapeutic development Standalone biomarker discovery or therapy platform development without an existing application to a specific PD-relevant therapeutic program Simple reformulation of an approved therapy without strong rationale for addressing a current unmet patient need Evaluation of dietary and other nutritional supplements given challenges in defining mechanism, establishing interpretable biomarker strategies and limited regulatory pathway clarity which are key pillars of this funding program Natural history studies or similar exploratory clinical data collection Deadlines and Review Schedules The program will be divided into two stages with the goal of offering applicants frequent opportunities to propose novel and promising PD therapeutics: Applicants may submit a pre-proposal application at any time.

Pre-proposals will be reviewed by MJFF within three weeks of submission. This stage is your first and best opportunity to determine if MJFF is the right partner for you. Applicants whose pre-proposal is selected for further consideration will be invited to submit a full proposal through one of the five review cycles (full proposal due dates in the sidebar).

MJFF staff will work with applicants to define the most flexible and fastest option for review. Invited applicants will have the opportunity to consult with MJFF on proposal development. Funding decisions will be communicated within three months of full proposal submission.

For questions about the application process or project suitability for this call for applications, please email [email protected] . Please note that MJFF has an Open Science Policy which governs research outputs (such as preprints, journal articles, data, code, and software) resulting from MJFF-funded work.

The Open Science Policy applies to this funding program and includes specific rules, timing, and format for the return of those research outputs and requires them to be shared openly, to be free to access, and with persistent identifiers. Please contact [email protected] for questions about the Open Science Policy. Here.

Until Parkinson's isn't. Help us speed a cure for the 6 million people worldwide living with Parkinson's. Join our email list to get the latest news and resources directly to your inbox.

Connection to Parkinson's Immediate family member has PD Immediate family member had PD Extended family member or friend has PD Extended family member or friend had PD I am a researcher, clinician or work with the PD community What Year Were You Diagnosed with PD?